Neuroanesthesia & neurocritical care
Systemic tolerance of intravenous milrinone administration for cerebral vasospasm secondary to non-traumatic subarachnoid hemorrhage
Authors' conclusion
Intravenous milrinone for CVS treatment seems associated with significant impact on systemic hemodynamics leading sometimes to treatment discontinuation.
Study context
- Population
- Patients receiving intravenous milrinone for cerebral vasospasm secondary to non-traumatic subarachnoid hemorrhage (SAH)
- Participants
- 91 patients
- Outcome
- Hemodynamic, respiratory and renal effects of milrinone (before vs after initiation)
- Follow-up
- Day - 1, baseline, day 1 and day 2
Methodological detailssingle-centre, observational
- Single-centre
- Observational
Main finding
As reported in the abstract
CO, baseline vs day 2 (median [IQR]), p < 0.001
4.5 L/min [3.4-5.2] vs 6.6 L/min [5.2-7.7]
MAP, baseline vs day 2, p = 0.001
101 mmHg [94-110] vs 95 mmHg [85-102]
Norepinephrine requirement, before milrinone vs day 1, p = 0.002
32% vs 58%
PaO2/FiO2 ratio, baseline vs day 2 (slight deterioration), p = 0.016
401 [333-406] vs 348 [307-357]
Observational data: associations, not effects.
Further findings
Favorable neurological outcome · 3-6 months
- Favorable outcome
- 55%
Safety
Milrinone interruption
- Milrinone interrupted
- 8%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →